Novartis AG is headed for an uptick but not for more than a year: that was the message from CEO Joe Jimenez as the company reported its third-quarter results. “The future of this company is not about 2017: it’s about 2018, 2019, 2020,” said Jimenez, responding to questioning by analysts on specific challenges the firm faces, notably the under-performance of its Alcon Inc. eye care division and the ongoing ramp-up in generic competition to its blockbuster drug Gleevec (imatinib), which will face European genericization from December 2016 on top of the existing competition in the US.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?